Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Trading Up 0.6 %

Shares of Anavex Life Sciences stock traded up $0.05 during trading hours on Friday, hitting $8.52. 838,214 shares of the company's stock traded hands, compared to its average volume of 1,356,018. The company has a fifty day simple moving average of $9.94 and a 200-day simple moving average of $7.72. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $14.44.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on AVXL shares. D. Boral Capital restated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Wednesday. HC Wainwright restated a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, January 28th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.